Page 92 - 78_02

RADIOFÁRMACOS..

10. Okarvi,
s.M,
Al
Jammaza,
I.
(2010).
Synthesis
and
evaluation
of
a
technetium-­-99m
labeled

cytotoxic
bombesin
peptide
conjugate
for
targeting

bombesin
receptor-­-expressing
tumors.

Nuc
Med

Biol,
37(3),
277-­-288.

11. Gambini,
J.P.,
Cabral,
P.,
Alonso,
O.,
Savio,
E.,
Figueroa,
S.D.,
Zhang,
X.et
al.
(2011).
Evaluation

of
99mTc-­-glucarate
as
a
breast
cancer
imaging
agent
in
a
xenograft
animal
model.
Nuc
Med
Biol

38(2)
255-­-60.

12. Ocampo-­-García,
B.E.,
Ramirez
F.
de
M.,
Ferro-­-Flores, G.et al. (2011). 99mTc-­-labelled
gold

nanoparticles
capped
with
HYNIC-­-peptide/mannose
for
sentinel
lymph
node
detection.

Nuc
Med
Biol,
38(1),
1-­-11.

13. Lua,
J.,
Panga,
Y.,
Xie,
F.
et
al.(2011).
Synthesis
and
in
vitro/in
vivo
evaluation
of
99mTc-­-labeled

folate
conjugates
for
folate
receptor
imaging.
Nuc
Med
Biol,
38(4),
557-­-565.

14. Jianguo,
L.,
Ling,
Q.,
Wen,
Ch.,
Shiening,

L.,
Wanzhong,
Y.(2011).
Preparation
and
in
vivo

biological
investigations
on
a
novel
radioligand
for
bone
scanning:
technetium-­-99m-­-labeled

zoledronic
acid
derivative.
Nuc Med Biol 38(5), 619-629.

15. Ohshima, Y., Hanaoka, H., Watanabe, S., Sugo, Y., Watanabe, S., Tominaga, H. et al. (2011).
Preparation and biological evaluation of 3-[76Br]bromo-a-methyl-l-
tyrosine, a novel tyrosine

analog for positron emission tomography imaging of tumors. Nuc Med Biol ,38:(6), 857-865.

16. Wagner, H.N., Wiseman, G.A., Marcus, C.S. et al. (2002). Administration Guidelines for
Radioinmunotherapy of Non-Hodkin’s Lymphoma with 90Y-Labeled Anti- CD20 Monoclonal
Antibody. J. Nucl.Med 43(2), 267-272.

17. Salouti, M., Babaei, M.H., Rajabi, H., Rasaee, M. (2011). Preparation and biological evaluation of
177Lu conjugated PR81 for radioimmunotherapy of breast cancer. Nuc Med Biol 38(6), 849-855.

18. Lehenberger, S., Barkhausen, C., Cohrs, S., Fischer, E., Grünberg, J., Hohn, A. et al. (2011). The
low-energy ß- and electron emitter 161Tb as an alternative to 177Lu
for targeted radionuclide

therapy. Nuc Med Biol , 38(6), 917-924.

19. Ya-Jen Changa, 1, Chih-Hsien Changa, 1, Chia-Yu Yua, Tsui-Jung Changa, Liang-Cheng Chena,
Min-Hua Chenb et al (2010). Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-
liposome in a C26 murine colon carcinoma solid tumor model. Nuc Med Biol 37(1), 95-104.

20. Kennel,
S.J.,
Lankford,
T.,
Garland,
M.,
Sundberg,

J.P.,
Mirzadeh,

S.
(2005).

Biodistribution
of

225Ra
citrate
in
mice:
retention
of
daughter
radioisotopes
in
bone.
Nuc
Med

Biol,32(8),
859-­-
867.

21. Nayak, T.K., Norenberg, J.P., Anderson, T.L., Prossnitz, E.R., Stabin, M.G., Atcher, R.W. (2007).

Somatostatin-­-receptor-­-targeted
a-­-emitting
213Bi
is

therapeutically
more
effective
than
ß--­-
emitting
177Lu
in
human
pancreatic
adenocarcinoma
cells.
Nuc
Med
Biol
34(2),
185-­-193.

22. 22.

Dahle, J., Borrebæk, J., Melhus, K.B., Bruland, Ø. .S, Salberg, G., Olsen, D.R. et al. (2006).
Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate a-particle
radioimmunotherapy Nuc Med Biol 33(2), 271—279.

23. Su, F-M, Beaumier, P., Axworthy, D., Atcher, R., Fritzberg A. (2005). Pretargeted
radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. Nuc Med Biol 32(7),
741-747.

24. Talanov,
V.S.,
Garmestani,
K.,
Regino,
C.A.S.,

Milenic,
D.E.,

Plascjak,
P.S.,
Waldmann,
T.A.
et
al.

(2006).
Preparation
and
in
vivo
evaluation
of
a
novel
stabilized
linker
for
211At
labeling
of

protein.
Nuc
Med

Biol,
33(4),
469-­-480.

229